Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Assertio Holdings, Inc.ASRT · Entity 37706 | Director | December 05, 2020 | December 07, 2020 |
| Assertio Therapeutics, IncASRT · Entity 149352 | Director · Director, President and CEO | February 12, 2020 | February 12, 2020 |
| ECOLAB INC.ECL · Entity 2954 | Director | March 31, 2025 | April 02, 2025 |
| ZIMMER BIOMET HOLDINGS, INC.ZBH · Entity 3278 | Director | September 30, 2026 | October 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Assertio Holdings, Inc.
Report date December 05, 2020 · Filed December 07, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 564,239 |
Reported balance
After 2020-12-05 transaction · row 1
1 source rowRow 1 · 2020-12-05 · Exercise / conversion · Acquired 73,529 · Balance 564,239 |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Expires 2020-12-05 | Direct | 0 |
Reported balance
After 2020-12-05 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-12-05 · Exercise / conversion · Disposed 73,529 · Balance 0 F1: Each restricted stock unit represents the contingent right to receive one share of common stock. This transaction represents the settlement of vested restricted stock units in shares of common stock. F2: The derivative securities were granted to the reporting person, and were not sold to the reporting person. As such, the reporting person did not pay any consideration for the derivative securities. |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 175,000 |
Reported balance
Holding disclosure · report date 2020-12-05 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 175,000 |
| Common StockSEC Table I · non-derivative | IndirectBy Child | 3,000 |
Reported balance
Holding disclosure · report date 2020-12-05 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 3,000 |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents the contingent right to receive one share of common stock. This transaction represents the settlement of vested restricted stock units in shares of common stock.
F2: The derivative securities were granted to the reporting person, and were not sold to the reporting person. As such, the reporting person did not pay any consideration for the derivative securities.
Assertio Therapeutics, Inc
Report date February 12, 2020 · Filed February 12, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 244,739 |
Ending reported balance
After 2020-02-12 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2020-02-12 · Exercise / conversion · Acquired 97,412 · Balance 275,747 Row 2 · 2020-02-12 · Tax withholding · Disposed 31,008 · Balance 244,739 F1: Represents shares of common stock withheld for payment of taxes upon the vesting of restricted stock units. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Expires 2022-02-12 | Direct | 194,825 |
Reported balance
After 2020-02-12 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-02-12 · Exercise / conversion · Disposed 97,412 · Balance 194,825 F2: Each restricted stock unit represents the contingent right to receive one share of common stock. This transaction represents the settlement of vested restricted stock units in shares of common stock. F4: The derivative securities were granted to the reporting person, and were not sold to the reporting person. As such, the reporting person did not pay any consideration for the derivative securities. F3: One-third of these restricted stock units are scheduled to vest on each of February 12, 2020, 2021 and 2022. |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 175,000 |
Reported balance
Holding disclosure · report date 2020-02-12 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 175,000 |
| Common StockSEC Table I · non-derivative | IndirectBy Child | 3,000 |
Reported balance
Holding disclosure · report date 2020-02-12 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 3,000 |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock withheld for payment of taxes upon the vesting of restricted stock units.
F2: Each restricted stock unit represents the contingent right to receive one share of common stock. This transaction represents the settlement of vested restricted stock units in shares of common stock.
F3: One-third of these restricted stock units are scheduled to vest on each of February 12, 2020, 2021 and 2022.
F4: The derivative securities were granted to the reporting person, and were not sold to the reporting person. As such, the reporting person did not pay any consideration for the derivative securities.
ECOLAB INC.
Report date March 31, 2025 · Filed April 02, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 26,741.32 |
Reported balance
After 2025-03-31 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-03-31 · Grant · Acquired 134.16 · Balance 26,741.32 F1: Includes 72.09 shares acquired pursuant to a dividend reinvestment feature of the Ecolab Inc. 2001 Non-Employee Director Stock Option and Deferred Compensation Plan. |
| Common StockSEC Table I · non-derivative | Direct | 26,865.54 |
Reported balance
After 2025-03-31 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2025-03-31 · Grant · Acquired 124.22 · Balance 26,865.54 |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 72.09 shares acquired pursuant to a dividend reinvestment feature of the Ecolab Inc. 2001 Non-Employee Director Stock Option and Deferred Compensation Plan.
ZIMMER BIOMET HOLDINGS, INC.
Report date September 30, 2026 · Filed October 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Phantom Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $89.85 | Direct | 38,077.496 |
Reported balance
After 2026-09-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-30 · Grant · Acquired 306.066 · Balance 38,077.496 F1: The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. F2: The Conversion or Exercise Price of Derivative Security is 1-for-1. F3: Units are to be settled in cash in ten annual installments commencing within sixty days after the end of the calendar year in which the cessation of the reporting person's service as a Director occurs. F4: Includes 96.739 phantom stock units accrued on July 31, 2026 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.
F2: The Conversion or Exercise Price of Derivative Security is 1-for-1.
F3: Units are to be settled in cash in ten annual installments commencing within sixty days after the end of the calendar year in which the cessation of the reporting person's service as a Director occurs.
F4: Includes 96.739 phantom stock units accrued on July 31, 2026 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 31, 2016 Filed Jan 4, 2017 20:52 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | GrantPhantom Stock Units · Derivative | 258.729 | $0.00 Strike: $103.39 | $0.00 |
DisclosureSEC source: 0000911916-17-000014 · edgar.xml · derivative · entry 1 HIGGINS ARTHUR J · CIK 0001142083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,436.091 Underlying: Common Stock · 258.729 shares Expires not disclosed F1 · security: The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1. F3 · derivative.exercise_date: Units are to be settled in cash in ten annual installments commencing within sixty days after the end of the calendar year in which the cessation of the reporting person's service as a Director occurs. F3 · derivative.expiration_date: Units are to be settled in cash in ten annual installments commencing within sixty days after the end of the calendar year in which the cessation of the reporting person's service as a Director occurs. F4 · balance_after: Includes 37.197 phantom stock units accrued on October 28, 2016 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| September 30, 2016 Filed Oct 4, 2016 20:42 UTC | ECOLAB INC. ECL · Entity 2954 | GrantCommon Stock | 216.25 | $121.39 | $26,249.51 |
DisclosureSEC source: 0001179110-16-030293 · edgar.xml · nonDerivative · entry 2 HIGGINS ARTHUR J · CIK 0001142083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,743.26 F1 · balance_after: Includes 37.09 shares acquired pursuant to a dividend reinvestment feature of the Ecolab Inc. 2001 Non-Employee Director Stock Option and Deferred Compensation Plan. Read SEC document |
| September 30, 2016 Filed Oct 4, 2016 20:42 UTC | ECOLAB INC. ECL · Entity 2954 | GrantCommon Stock | 205.96 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-16-030293 · edgar.xml · nonDerivative · entry 1 HIGGINS ARTHUR J · CIK 0001142083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,489.92 Read SEC document |
| September 30, 2016 Filed Oct 4, 2016 20:24 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | GrantPhantom Stock Units · Derivative | 206.771 | $0.00 Strike: $129.37 | $0.00 |
DisclosureSEC source: 0000911916-16-000672 · edgar.xml · derivative · entry 1 HIGGINS ARTHUR J · CIK 0001142083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,140.165 Underlying: Common Stock · 206.771 shares Expires not disclosed F1 · security: The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1. F3 · derivative.exercise_date: Units are to be settled in cash in ten annual installments commencing within sixty days after the end of the calendar year in which the cessation of the reporting person's service as a Director occurs. F3 · derivative.expiration_date: Units are to be settled in cash in ten annual installments commencing within sixty days after the end of the calendar year in which the cessation of the reporting person's service as a Director occurs. F4 · balance_after: Includes 34.637 phantom stock units accrued on July 29, 2016 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.